Funding sources: The ‘Medical Research during residency Program’ Fund – granted by the Faculty of Health Sciences, Ben-Gurion University of the Negev, and Soroka University Medical Center.
Detection of S100B in maternal blood before and after fetal death
Article first published online: 2 JAN 2014
© 2013 John Wiley & Sons, Ltd.
Volume 34, Issue 1, pages 94–97, January 2014
How to Cite
Beharier, O., Shusterman, E., Eshcoli, T., Szaingurten-Solodkin, I., Aricha-Tamir, B., Weintraub, A. Y., Sheiner, E., Holcberg, G. and Hershkovitz, R. (2014), Detection of S100B in maternal blood before and after fetal death. Prenat. Diagn., 34: 94–97. doi: 10.1002/pd.4266
Conflicts of interest: None declared
- Issue published online: 2 JAN 2014
- Article first published online: 2 JAN 2014
- Accepted manuscript online: 31 OCT 2013 10:50AM EST
- Manuscript Accepted: 21 OCT 2013
- Manuscript Revised: 23 SEP 2013
- Manuscript Received: 11 JUN 2013
S100B is a brain damage biomarker. When measured immediately after birth, it reflects neonatal brain damage following asphyxia. In this study, we used feticide as a novel model of fetal brain damage. We examined whether such damage is reflected by a rise in S100B in maternal blood before delivery.
Eight pregnant women were recruited between January and July 2012. Maternal blood samples were drawn before and after feticide at predetermined time points (0, 15, 30, 60, 120, and 240 min). S100B, lactate dehydrogenase, creatine kinase, and creatinine concentrations were measured by standard human ELISA and chemical analyzer.
No significant difference was noted between S100B levels before and after feticide, neither in non-specific cell death markers (lactate dehydrogenase and creatine kinase), which remained within normal range. S100B ranged between 0.015–0.04 µg/L through all the predetermined time points.
No statistically significant differences were demonstrated in S100B levels before and after feticide. © 2013 John Wiley & Sons, Ltd.